Monoclonal Antibodies

Pic:getty/gajus

Sanofi to acquire Kymab for up to $1.45bn

By Rachel Arthur

Sanofi will acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies. The acquisition will give it global rights to KY1005, which has the potential to treat a range of immune-mediated diseases and inflammatory...

© GettyImages/YurolaitsAlbert

Lilly's COVID-19 antibody trial on hold over safety concerns

By Jane Byrne

Enrollment is temporarily on hold in the ACTIV-3 clinical trial, which is evaluating Lilly's investigational neutralizing antibody bamlanivimab (LY-CoV555) as a treatment for COVID-19 in hospitalized patients. The pause was recommended by the study's...

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers